Middle East and Africa Travel Vaccines Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Hepatitis A, Hepatitis B, Meningococcal Vaccines, and Others) and Application (Domestic Travel and Outbound Travel)

The travel vaccines market in MEA is expected to grow from US$ 120.13 million in 2021 to US$ 167.76 million by 2028; it is estimated to grow at a CAGR of 4.9% from 2021 to 2028.

Continuous demand for life-saving vaccines is the major factor leading to the growth of the travel vaccines market in the region. Vaccines are essential in providing immunity against infectious diseases. Success stories of eradicating smallpox and polio by vaccines inspired many researchers and manufacturing companies. In recent times, vaccines helped control and prevent COVID–19 to a large extent. Moreover, factors such as the growing population, the MEA travel underlying mutations of bacteria and virus, and the development of new threats that require rapid solutions are likely to boost the demand for vaccines and are expected to flourish the market growth during the forecast period.

Despite several manufacturing challenges, vaccine production increased significantly. Technological developments enabled researchers and manufacturing companies to offer potential changes in the formulation, production, and development of vaccines. Also, growing developments in the healthcare industries in developing countries triggered the development and production of vaccines. Such programs are likely to increase the production of vaccines and meet the never-ending demand for immunization in the future.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA travel vaccines market. The MEA travel vaccines market is expected to grow at a good CAGR during the forecast period.     

 MEA Travel Vaccines Market Revenue and Forecast to 2028 (US$ Million)

MEA Travel Vaccines Market Segmentation              

The MEA travel vaccines market is segmented into product, application, and country. The MEA travel vaccines market, based on product, is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others. In 2021, others segment held the largest share of the market. The MEA travel vaccines market, based on application, is segmented into domestic travel and outbound travel. In 2021, the outbound travel segment held the largest share of the market. Based on country, the MEA travel vaccines market is segmented into Saudi Arabia, South Africa, UAE, and the Rest of the MEA.    

Abbott; Bharat Biotech; GlaxoSmithKline plc; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; and Sanofi are among the leading companies in the travel vaccines market in the region.

1. Abbott
2. Bharat Biotech
3. GlaxoSmithKline plc
4. Merck & Co., Inc.
5. Novartis AG
6. Pfizer Inc.
7. Sanofi

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the MEA travel vaccines market
• Highlights key business priorities in order to assist companies to realign their business strategies 
• The key findings and recommendations highlight crucial progressive industry trends in the MEA travel vaccines market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the travel vaccines market, as well as those hindering it 
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution